New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies

Initial data from the first multi-dose cohort of RA study to be presented

Initial data from the first multi-dose cohort of velinotamig study also to be shared

Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives

The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City